May 8, 2017May 8, 2017

Merck’s Keytruda Therapy for Certain Classical Hodgkin Lymphoma Patients Wins European Approval

News

The European Commission has approved the immune checkpoint inhibitor Keytruda (pembrolizumab) to treat certain Hodgkin lymphoma patients in 31 European countries, Merck announced. The approval applies to patients with relapsed or refractory classical ... Read more

April 4, 2016May 13, 2016

EMA Agrees to Consider Opdivo (nivolumab) as a Possible Treatment for Classical Hodgkin’s Lymphoma

News

Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application of Opdivo (nivolumab), which seeks to extend Opdivo’s current indications to include the treatment of classical Hodgkin’s lymphoma (cHL) patients after prior therapies. The ... Read more